Meridian Bioscience (VIVO) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Adobe CFO Dan Durn to depart company in June 2026
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
July 23, 2015 8:00 AM EDTCINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported fiscal 2015 third quarter and first nine months net revenues of $48.2 million and $147.8 million, respectively, increases of 2% and 4%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $14.4 million, an increase of 10% from the same period of the prior fiscal year; reported nine months operating income of $42.8... More